Key clinical point: A subset of patients with follicular lymphoma are vulnerable to organ dysfunction or transformation without treatment.
Major finding: A total of 58 patients (24.4%) had organ dysfunction or transformation at the time of progression and had worse survival outcomes, compared with patients who did not experience those events.
Study details: A retrospective study including data on 238 patients with grade 1-3a follicular lymphoma aged 18-70 years who were managed with watchful waiting.
Disclosures: Study authors reported disclosures related to Janssen, Gilead Sciences, Lundbeck, Roche, AbbVie, Amgen, Seattle Genetics, Bristol-Myers Squibb, Servier Laboratories, and Merck.
Davies GA et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 28. doi: 10.1016/j.clml.2018.08.015
This Week's Must Reads
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Watchful waiting in follicular lymphoma, Davies GA et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 28. doi: 10.1016/j.clml.2018.08.015
ASCO Guideline on Alcohol Consumption and Cancer, J Clin Oncol; 2018 Jan; LoConte, Brewster, et al
Cochrane On Bisphosphonates for Prostate Cancer, Cochrane; 2017 Dec 26; Macherey, Monsef, et al
Cochrane on Vaccine-Based Immunotherapy for NSCLC, Cochrane; 2017 Dec 16; Zhu, Li, Tiselius, et al